Ipsen Unveils Corabotase: A Potential Breakthrough in Lasting Wrinkle Reduction
What we know Ipsen, a global biopharmaceutical company, recently presented late-breaking Phase II clinical trial data for corabotase, a first-in-class recombinant neuroinhibitor designed to treat moderate-to-severe glabellar lines (the deep